Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years as part of a phased rollout of the popular drug.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

In the 176-week study run over three years – which underpinned tirzepatide's approval for obesity last year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg ...

Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide ... Weekly tirzepatide injections (5 mgi, 10 mg, 15 mg) significantly reduced the risk of progression to type 2 diabetes ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly’s Mounjaro was added to the FDA’s drug shortage database in 2022, while Zepbound was added this April. Eli Lilly did not immediately respond to a request for comment from Quartz.